Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.

by on March 2, 2016

Authors: Balhara YP
PMID: 24380101 [PubMed – indexed for MEDLINE] (Source: Journal of Opioid Management)

Previous post: Buprenorphine/naloxone pediatric ingestion: Exposure rates differ between film and tablet formulations

Next post: Analysis of ‘Revolving Door' Patients in Opioid Dependent Patients: the Impact of Treatment Discontinuation on Relapse Rates and Health Care Costs in us Public Health Insurance Claims

Copyright 2011 Oxycontin Treatment Directory | Oxycontin Treatment Directory | All About Suboxone | About | Disclaimer | Privacy Policy Built On The Thesis Theme for WordPress

WordPress Admin

Discuss Treatment

Call 877-841-0678

X